MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.57
-0.12
-1.38%
After Hours: 8.68 +0.11 +1.28% 19:45 03/04 EST
OPEN
8.66
PREV CLOSE
8.69
HIGH
8.72
LOW
8.39
VOLUME
4.91M
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
2.15B
P/E (TTM)
7.10
1D
5D
1M
3M
1Y
5Y
1D
BioCryst reports inducement grants under Nasdaq listing rule
TipRanks · 20h ago
BioCryst grants 65,850 RSUs to six new hires under Nasdaq inducement rule
Reuters · 20h ago
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
Seeking Alpha · 1d ago
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio Expansion - Has The Bull Case Changed?
Simply Wall St · 2d ago
BioCryst price target raised to $22 from $21 at Wedbush
TipRanks · 2d ago
Weekly Report: what happened at BCRX last week (0223-0227)?
Weekly Report · 2d ago
Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value
TipRanks · 5d ago
BioCryst Earnings Call Highlights Profits, Pipeline Momentum
TipRanks · 5d ago
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.